Overview

Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial

Status:
Terminated

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

Endostar ® (recombinant human endostatin) continuous intravenous infusion combined with mPFC neoadjuvant treatment of esophageal cancer arm, Ⅱ single-center clinical trial.

Phase:

Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Treatments:

Cisplatin
Endostar protein
Tegafur